Cutaneous manifestations secondary to panitumumab therapy

Clin Dermatol. 2021 Sep-Oct;39(5):887-889. doi: 10.1016/j.clindermatol.2021.07.014. Epub 2021 Aug 8.

Authors

Michael Joseph Lavery¹, Leigh Forsyth², Elaine Hindle³

Affiliations

¹ Department of Dermatology, St. Helens and Knowsley Teaching Hospitals, NHS Trust, Rainhill, United Kingdom; Division of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA. Electronic address: [email protected].
² Department of Histopathology, St. Helens and Knowsley Teaching Hospitals, NHS Trust, Rainhill, United Kingdom.
³ Department of Dermatology, St. Helens and Knowsley Teaching Hospitals, NHS Trust, Rainhill, United Kingdom.

PMID: 34785017
DOI: 10.1016/j.clindermatol.2021.07.014

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal* / adverse effects
Antineoplastic Combined Chemotherapy Protocols
Humans
Panitumumab / adverse effects
Skin Neoplasms* / chemically induced
Skin Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal
Panitumumab